Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 901–1,000 of 1,010
New oral anticoagulants for the treatment of venous thromboembolism
Agnelli, G., Becattini, C., & Franco, L. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.005 · Cited by 23
Dobesh, P. P., & Fanikos, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0301-x · Cited by 24
Barbar, S., Milan, M., Campello, E., Spiezia, L., Piovella, C., Pesavento, R., & Prandoni, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0396 · Cited by 26
The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses
Schulman, S., & Majeed, A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300946 · Cited by 23
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.009 · Cited by 26
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE
Bach, M., & Bauersachs, R. M. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0486 · Cited by 23
Roetker, N. S., Lutsey, P. L., Zakai, N. A., Alonso, Á., Adam, T. J., & MacLehose, R. F. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668521 · Cited by 23
Dentali, F., Minno, M. N. D. D., Gianni, M., Ambrosino, P., Squizzato, A., & Ageno, W. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1249-x · Cited by 26
“Six studies [14–19] for a total of 27,023 patients with acute VTE were included in the analysis.”
BackgroundMethodAlbumin and bleed risk in rivaroxaban treated patients
Wojakowski, E., Cheruvil, C., Hassan, A. K., Holsen, M. R., Chen, L., Rossi, M., Wilcox, N., & Woodruff, A. E. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02092-w · Cited by 24
Lindhoff‐Last, E., Birschmann, I., Kühn, J., Lindau, S., Konstantinides, S., Grottke, O., Nowak‐Göttl, U., Lucks, J., Zydek, B., von Heymann, C., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1549-6556 · Cited by 23
Venous thromboembolism mortality and trends in older US adults, 2011–2019
Giorgio, K., Walker, R. F., MacLehose, R. F., Herrera, D. A., Wang, W., Alonso, Á., Zakai, N. A., & Lutsey, P. L. (2023) · American Journal of Hematology · doi:10.1002/ajh.26996 · Cited by 25
Rivaroxaban for the treatment and prevention of thromboembolic disease
Antoniou, S. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12387 · Cited by 26
A Novel Synthesis of the Oxazolidinone Antithrombotic Agent Rivaroxaban
Yuan, J., Liu, K., Li, L., Yuan, Y., Liu, X., & Li, Y. (2014) · Molecules · doi:10.3390/molecules190914999 · Cited by 23
Activated protein C accelerates venous thrombus resolution through heme oxygenase‐1 induction
Gabre, J. T., Chabasse, C., Cao, C., Mukhopadhyay, S., Siefert, S. A., Bi, Y., Netzel–Arnett, S., Sarkar, R., & Zhang, L. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12424 · Cited by 23
Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?
Arepally, G. M., & Ortel, T. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024633 · Cited by 27
Noble, S., & Sui, J. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30115-3 · Cited by 24
Direct oral anticoagulants (DOAC) – Management of emergency situations
Lindhoff‐Last, E. (2017) · Hämostaseologie · doi:10.5482/hamo-16-11-0043 · Cited by 23
Temporal trends in outpatient management of incident pulmonary embolism and associated mortality
Klil-Drori, A. J., Coulombe, J., Suissa, S., Hirsch, A., & Tagalakis, V. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.10.026 · Cited by 24
Bartoli-Abdou, J., Patel, J. P., Crawshaw, J., Vadher, B., Brown, A. H., Roberts, L. N., Patel, R., Arya, R., & Auyeung, V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.021 · Cited by 24
CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis
Sychev, D. A., Vardanyan, A. V., Rozhkov, A. V., Hachatryan, E., Badanyan, A., Vv, S., Ananichuk, A. V., & Денисенко, Н. П. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2017.0152 · Cited by 23
Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time
Bae, J., Kim, H.-W., Kim, W., Kim, S., Park, J., Jung, D., & Yu, D. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15478 · Cited by 23
“The plasma anti-Xa concentration range of 140-260 ng/mL was considered an effective thromboprophylactic antiXa concentration range of rivaroxaban in studies of humans.(1,3,10,27,31,32) As a result, strong statistical correlations were observed between antiXa concentration and PT as well as TEG activated with tissue fa…”
BackgroundLee, J. H., Hyun, D., Choi, C., Lee, J. C., Kim, W. S., Oh, Y., Lee, S., & Lee, J. S. (2019) · Respiration · doi:10.1159/000499895 · Cited by 23
Korobey, M. J., Sadaka, F. G., Javed, M. A., Moynihan, M., & Alsaei, A. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00968-6 · Cited by 23
Okumura, Y., Fukuda, I., Nakamura, M., Yamada, N., Takayama, M., Maeda, H., Yamashita, T., Ikeda, T., Mo, M., Kobayashi, T., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0636 · Cited by 27
Zhang, X. Y., Huang, J., Peng, Z., Lu, X., Yang, X., & Ye, K. (2020) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.11.050 · Cited by 23
Wik, H. S., Kahn, S. R., Eriksson, H., Morrison, D., Ghanima, W., Schulman, S., & Sandset, P. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15449 · Cited by 24
Immunotherapy in antiphospholipid syndrome
López-Pedrera, C., Aguirre, M. A., Ruiz‐Limón, P., Pérez‐Sánchez, C., Jiménez, Y., Barbarroja, N., & Cuadrado, M. J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.006 · Cited by 24
Bleeding and clotting in hereditary hemorrhagic telangiectasia
Dittus, C. E., Streiff, M., & Ansell, J. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.330 · Cited by 25
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., & Kesteven, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957 · Cited by 23
Amin, A., Jing, Y., Trocio, J., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.950670 · Cited by 22
Sindet-Pedersen, C., Pallisgaard, J. L., Olesen, J. B., Gislason, G. H., & Arevalo, L. C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.022 · Cited by 22
Piati, P. K., Peres, A. K., de Andrade, D. O., Jorge, M. A., & Toregeani, J. F. (2019) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.180111 · Cited by 21
Karakasis, P., Ktenopoulos, N., Pamporis, K., Sagris, Μ., Σουλαϊδόπουλος, Σ., Gerogianni, M., Leontsinis, I., Giannakoulas, G. A., Tousoulis, D., Fragakis, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133784 · Cited by 26
How to prevent, treat, and overcome current clinical challenges of VTE
van Es, J., Eerenberg, E. S., Kamphuisen, P. W., & Buller, H. R. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04334.x · Cited by 24
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 23
Aspirin in the primary prophylaxis of venous thromboembolism in surgical patients
Sahebally, S. M., Healy, D. A., & Walsh, S. R. (2015) · The Surgeon · doi:10.1016/j.surge.2015.05.001 · Cited by 23
Loffredo, L., Perri, L., Ben, M. D., Angelico, F., & Violi, F. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1171-7 · Cited by 27
“A total of 7 studies [24–30] met the inclusion criteria and were included in this systematic review.”
BackgroundManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Finks, S. W., Trujillo, T. C., & Dobesh, P. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632785 · Cited by 24
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
Brown, K. S., Zahir, H., GROSSO, M. A., Lanz, H., Mercuri, M. F., & Levy, J. H. (2016) · Critical Care · doi:10.1186/s13054-016-1422-2 · Cited by 27
Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism
Ghazvinian, R., Gottsäter, A., & Elf, J. L. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1607-9 · Cited by 23
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment
Schindewolf, M., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400302 · Cited by 23
Fernandez‐Martinez, S., Lenoir, C., Samer, C. F., & Rollason, V. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040250 · Cited by 23
Fukasawa, T., Seki, T., Nakashima, M., & Kawakami, K. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15799 · Cited by 24
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Linnemann, B., Beyer‐Westendorf, J., Espinola–Klein, C., Mühlberg, K. S., Müller, O. J., & Klamroth, R. (2024) · Hämostaseologie · doi:10.1055/a-2178-6574 · Cited by 32
Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants
Scridon, A., & Şerban, R. C. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000247 · Cited by 22
Risk of Gastrointestinal Bleeding with Dabigatran: A Head-to-Head Comparative Study with Rivaroxaban
Sherid, M., Sifuentes, H., Sulaiman, S., Samo, S., Husein, H., Tupper, R. S., Thiruvaiyaru, D. S., Spurr, C., & Sridhar, S. (2014) · Digestion · doi:10.1159/000365967 · Cited by 27
A new paradigm shift in antithrombotic therapy
Pudusseri, A., Shameem, R., & Spyropoulos, A. C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00133 · Cited by 25
“The primary efficacy outcome was seen in 6.7% of the enoxaparin group vs. 6.0% of the dabigatran etexilate 220 mg group and 8.6% of the dabigatran etexilate 150mg group.”
BackgroundInfluentialAgeno, W., Crowther, M. A., Baglin, T. P., Falanga, A., Buller, H. R., & Palareti, G. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12038 · Cited by 22
Guðmundsdóttir, B. R., Francis, C. W., Bjornsdottir, A. M., Nellbring, M., & Onundarson, P. T. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.013 · Cited by 31
Venous Thromboembolism Overview
Battinelli, E. M., Murphy, D. L., & Connors, J. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.010 · Cited by 23
Alternative to oral dicoumarin anticoagulants: Considerations in dental care
Mingarro-de-Leon, A., & Chaveli-Lopez, B. (2013) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.51226 · Cited by 22
New oral anticoagulants in the ED setting: a review
Pollack, C. V. (2012) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2012.04.005 · Cited by 22
“Secondary VTE prevention In the Continued Treatment Study, patients with symptomatic DVT or PE who had been treated for 6 to 12 months with warfarin or rivaroxaban were randomized to receive either rivaroxaban 20 mg orally once daily or placebo for 6 or 12 months [12].”
BackgroundMethodInfluentialBoland, M. R., Murphy, M., Murphy, M., & McDermott, E. W. M. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-129 · Cited by 22
“In addition, a Phase III study of low-dose rivaroxaban in patients with acute coronary syndrome is also underway after a recent Phase II study showed that it may reduce major ischemic events [5,6].”
BackgroundIhaddadene, R., & Carrier, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1120718 · Cited by 23
Cancer-associated thrombosis in Asia
Angchaisuksiri, P. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0110-4 · Cited by 26
Lusk, K. A., Snoga, J. L., Benitez, R. M., & Sarbacker, G. B. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017707126 · Cited by 26
“6% and a minor bleeding risk of up to 14% per year.(1-20) Dabigatran is indicated in treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), stroke prevention in nonvalvular atrial fibrillation, and prophylaxis of DVT and PE following hip replacement surgery.”
BackgroundEvaluation of direct oral anticoagulants and vitamin K antagonists in mesenteric venous thrombosis
Salim, S., Ekberg, O., Elf, J. L., Zarrouk, M., Gottsäter, A., & Acosta, S. (2018) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355518779517 · Cited by 24
Update on extended treatment for venous thromboembolism
Peñaloza-Martínez, E., Rodríguez, P. D., Proietti, M., Fernández‐Llamazares, G. S., Mendo, C. L., Álvarez-Sala, J. L., Marra, A. M., & del Toro‐Cervera, J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1538564 · Cited by 26
“The EINSTEIN-EXT study [38] evaluated rivaroxaban for secondary VTE prevention after 670 E.”
MethodIt's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
Pedersen, M. H., Wahlsten, L. R., Grønborg, H., Gislason, G., Petersen, M. M., & Bonde, A. N. (2019) · The American Journal of Sports Medicine · doi:10.1177/0363546519876054 · Cited by 22
Valeriani, E., Porreca, E., Weitz, J. I., Schulman, S., Candeloro, M., & Nisio, M. D. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14807 · Cited by 26
Powell, M. Z., de Villers, K. T., Schwarz, K. A., Case, D. E., & Trujillo, T. C. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020952749 · Cited by 23
Ceresetto, J. M. (2016) · Clinics · doi:10.6061/clinics/2016(01)07 · Cited by 25
Phillippe, H. M., Hornsby, L. B., Eudaley, S. T., Armstrong, E. M., & Bellone, J. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530390 · Cited by 29
Therapeutic Potential of Oral Factor Xa Inhibitors
Hylek, E. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1012149 · Cited by 22
Fredman, D., McNeil, R., Eldar, O., Leader, A., Gafter-Gvili, A., & Avni, T. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02926-3 · Cited by 21
Sugie, M., Iizuka, N., Shimizu, Y., & Ichikawa, H. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.5045 · Cited by 22
“The Einstein-Extension Study, a randomized, doubleblind, placebo-controlled, superiority evaluated study, suggested that rivaroxaban 20 mg/day for a mean duration of approximately 6 months after the completion of treatment for 12 months with VKA following acute VTE was associated with significantly fewer recurrent con…”
BackgroundUse of novel oral anticoagulant agents in venous thromboembolism
Madan, S., Shah, S., Dale, P., Partovi, S., & Parikh, S. A. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.11.17 · Cited by 23
Chaudhury, A., Balakrishnan, A., Thai, C., Holmstrom, B., Nanjappa, S., Ma, Z., & Jaglal, M. V. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0895-8 · Cited by 21
Bromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
Cohen, A. T., Berger, S. E., Milenković, D., Hill, N. R., & Lister, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.017 · Cited by 22
Rodríguez, J., Kobus, V., Téllez, I. E. H., & Pérez, G. (2020) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2020.0209 · Cited by 23
Palumbo, J. S., Lensing, A. W. A., Brandão, L. R., Hooimeijer, H. L., Kenet, G., van Ommen, C. H., Pap, A. F., Majumder, M., Kubitza, D., Thelen, K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008160 · Cited by 22
Tijani, A., Coons, E. M., Mizuki, B., Dermady, M., Stanilova, K., Casey, A. L., Alqudsi, M., Gastañaduy, M., Elmayan, A., Bamnolker, A., et al. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221129348 · Cited by 21
Kubitza, D., Becka, M., Mück, W. M., & Kraetzschmar, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12349 · Cited by 22
Optimal treatment duration of venous thrombosis
Ageno, W., Dentali, F., Donadini, M. P., & Squizzato, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12234 · Cited by 21
Townshend, G., & Hull, R. D. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0931 · Cited by 21
“No difference in bleeding was seen between the two groups (33).”
BackgroundResultMichalski, F., Tittl, L., Werth, S., Hänsel, U., Pannach, S., Şahin, K., Weiss, N., & Beyer‐Westendorf, J. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0116 · Cited by 25
Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants
Lee, A. Y. Y., & Carrier, M. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50027-8 · Cited by 26
Eberg, M., Kahn, S. R., Azoulay, L., & Tagalakis, V. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-10-0775 · Cited by 23
Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions
Nakamura, M., Yamada, N., & Ito, M. (2017) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00015 · Cited by 24
Heisen, M., Treur, M., Heemstra, H. E., Giesen, E. B. W., & Postma, M. J. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1331912 · Cited by 21
Tomkowski, W. Z., Kuca, P., Urbanek, T., Chmielewski, D., Krasiński, Z., Pruszczyk, P., Windyga, J., Oszkinis, G., Jawień, A., Burakowski, J., et al. (2017) · Acta Angiologica · doi:10.5603/aa.2017.0008 · Cited by 27
“Apixaban (initial dose 10 mg twice daily recommended for the first 7 days) and rivaroxaban (initial higher dose 15 mg twice daily is used for the first 21 days) may be used as monotherapy in the acute phase of DVT and PE [23, 24].”
MethodTarango, C., Schulman, S., Betensky, M., & Goldenberg, N. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407241 · Cited by 21
Grandoni, F., & Alberio, L. (2019) · Cancers · doi:10.3390/cancers11010046 · Cited by 23
“In the subgroup analysis, 655 patients were randomly assigned to receive rivaroxaban versus VKAs (EINSTEIN-DVT and EINSTEIN-PE trials) [29,30,45], 771 patients assigned to receive edoxaban versus VKAs (Hokusai-VTE) [32,46], 335 patients assigned to receive dabigatran versus VKAs [33,47,48], and 159 patients assigned t…”
BackgroundMethodValorization of Carbon Dioxide into Oxazolidinones by Reaction with Aziridines
Lamb, K. J., Ingram, I. D. V., NORTH, M. J., & Sengoden, M. (2019) · Current Green Chemistry · doi:10.2174/2213346106666190321142328 · Cited by 22
Lee, J. H., Oh, Y., Lee, S., & Lee, J. S. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e160 · Cited by 21
Yamashita, Y., Yoshikawa, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.032 · Cited by 25
Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
Hayashi, T., Takatori, H., Horii, R., Nio, K., Terashima, T., Iida, N., Kitahara, M., Shimakami, T., Arai, K., Kitamura, K., et al. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1140-8 · Cited by 21
Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism
Quan, S., Smith, J. E., Wu, C. M., Koshman, S. L., Nguyen, B. V., & Bungard, T. J. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.01.011 · Cited by 22
Devata, S., Angelini, D. E., Blackburn, S. A., Hawley, A. E., Myers, D. D., Schaefer, J. K., Hemmer, M. V., Magnani, J. L., Thackray, H. M., Wakefield, T. W., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12279 · Cited by 23
Huang, H., Peng, C. C., Lin, S., Munir, K. M., Chang, R. H., Wu, B., Liu, P. P., Hsu, J., Loh, C., & Tu, Y. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019618 · Cited by 23
Oral anticoagulants in the management of venous thromboembolism
Makaryus, J. N., Halperin, J. L., & Lau, J. F. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.73 · Cited by 28
Robertson, L., & Kesteven, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956 · Cited by 22
Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615585991 · Cited by 20
Bleeding Risk in Hemodialysis Patients
van der Sluijs, A. V. E., Pai, P. M., Zhu, W., & Ocak, G. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151478 · Cited by 18
Nuevos anticoagulantes orales y su papel en la práctica clínica
Mateo, J. (2013) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(13)70057-8 · Cited by 58
Current Status of New Anticoagulants in the Management of Venous Thromboembolism
Montoya, R. C., & Gajra, A. (2012) · Advances in Hematology · doi:10.1155/2012/856341 · Cited by 22
Rudd, K. M., & Phillips, E. (. M. (2013) · Thrombosis · doi:10.1155/2013/973710 · Cited by 20
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.